Radiation Synovectomy: An Enticing Treatment Option for Inflammatory Joint Pain

Radiosynovectomy (RSV) represents an advanced therapeutic modality in nuclear medicine, designed to treat chronic inflammatory joint disorders that are unresponsive to conventional therapies. This targeted approach involves the intra-articular administration of radioactive microparticles containing a β^--emitting radionuclide, selectively eradicating the inflamed synovial membrane while preserving surrounding tissues. As a minimally invasive, nonsurgical procedure routinely performed in outpatient settings, RSV offers a compelling alternative to more invasive interventions. Over time, RSV has evolved significantly, transitioning from the empirical use of radiocolloids to the development of specialized agents tailored for different joint types. Advancements in this field continue to explore a variety of β^--emitting radionuclides with unique emission characteristics, integrated into novel microparticles to improve both specificity and therapeutic efficacy. The selection of an optimal radionuclide hinges on critical nuclear and chemical properties, ensuring effective binding to microparticles and delivering favorable clinical outcomes. This review examines the evolution of RSV in joint disorder management, detailing its mechanisms of action, key factors influencing radionuclide and microparticle selection, and the methodologies involved in their development and production. Additionally, it provides an overview of commonly used radionuclides and microparticles, evaluating their effectiveness within the ever-evolving landscape of RSV.